Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-20-062136
Filing Date
2020-05-15
Accepted
2020-05-15 08:46:12
Documents
47
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q tm2014647d1_10q.htm 10-Q 336887
2 EXHIBIT 31.1 tm2014647d1_ex31-1.htm EX-31.1 9685
3 EXHIBIT 32.1 tm2014647d1_ex32-1.htm EX-32.1 4463
  Complete submission text file 0001104659-20-062136.txt   3119671

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT ttnp-20200331.xml EX-101.INS 784950
5 XBRL TAXONOMY EXTENSION SCHEMA ttnp-20200331.xsd EX-101.SCH 27122
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ttnp-20200331_cal.xml EX-101.CAL 33433
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ttnp-20200331_def.xml EX-101.DEF 89273
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE ttnp-20200331_lab.xml EX-101.LAB 241353
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ttnp-20200331_pre.xml EX-101.PRE 197367
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-13341 | Film No.: 20880821
SIC: 2836 Biological Products, (No Diagnostic Substances)